Search published articles


Showing 2 results for Sabzali
Phylogenic Relationship of Salmonella Serovars Isolated from Different Foodstuffs in Isfahan
Somaieh Sabzali, Majid Bouzari,
Volume 14, Issue 4 (Jul-Aug 2020)
Abstract
   Background and objectives: are divided into two species: Salmonella enterica and Salmonella Salmonella bongori. S. enterica has more than 2,500 serotypes. Serovars of S. enterica such as Typhimurium, Enteritidis, Paratyphi B, Paratyphi A and Newport are associated with human infections. Approximately 75% of human Salmonella infections have been associated with contaminated food such as eggs, chicken, beef, pork, dairy products, fruits and vegetables. The aim of this study was to determine the frequency of Salmonella strains isolated from various food sources in Isfahan, Iran.
    Methods: Forty Salmonella strains were isolated from 450 suspected cases referred to the veterinary reference laboratory of Isfahan Province. The isolates were identified by differential and serotyping tests and then confirmed by PCR. A phylogenic tree was constructed with 34 sequences by neighbor-joining method using the MEGA7 software (version 7.1). 
    Results: Overall, 10 Salmonella serovars were isolated from 32 chicken meat, three beef and five egg shell samples. S. enterica serovar Ouakum (20%), S. Enteritidis (17.5%) and S. Typhimurium (17.5%) were the most common serovars, while S. enterica serovar Nitra (2.5%) was found as the least prevalent isolate.
    Conclusion: In this study, S. Typhimurium species is placed in different clusters along with sequences reported from different parts of the world, indicating that the serovars are circulating all over the world.

The effect of Sinopharm COVID-19 vaccine on fecal calprotectin levels and clinical symptoms in patients with ulcerative colitis
Babak Tamizifar , Nazila Kassaian , Marzieh Rahimkhorasani, Hazhir Moradi , Somaieh Sabzali , Kiana Shahzamani , Peyman Adibi ,
Volume 20, Issue 1 (1-2026)
Abstract
Background: The ongoing COVID-19 pandemic has raised concerns regarding the safety and efficacy of vaccination in immunocompromised patients, including those with inflammatory bowel disease (IBD). In this study, we aimed to investigate the effect of the Sinopharm anti-COVID-19 vaccine on fecal calprotectin (fCP) levels and clinical symptoms in patients with ulcerative colitis (UC).
Methods: A total of 28 patients with UC (8 females and 20 males), with a mean age of 40.8 ± 9.7 years, were enrolled in the study. Most patients were receiving 5-aminosalicylic acid (5-ASA) agents. All patients received the Sinopharm anti-COVID-19 vaccine. Fecal calprotectin levels and clinical symptoms were assessed at baseline and at 2 and 12 weeks after vaccination. The Lichtiger score and Mayo score were used to evaluate clinical symptoms.
Results: No IBD-related adverse events were reported following vaccination. There was no significant difference in fCP levels between baseline and 2 weeks after vaccination. However, a significant decrease in fCP levels was observed at 12 weeks after vaccination compared to baseline and 2 weeks post-vaccination. Similarly, a significant improvement in clinical symptoms was noted at 2 and 12 weeks after vaccination compared to baseline, as evidenced by a reduction in the Lichtiger score. There was no association between vaccination and the clinical bleeding score (Mayo score). None of the other parameters, including location of injury, type of medication, or sex, were associated with fCP levels, Lichtiger score, or Mayo score.
Conclusion: The results of this study suggest that the Sinopharm anti-COVID-19 vaccine is safe for patients with IBD and does not lead to exacerbation of UC symptoms.

Page 1 from 1